New stock news | JZ Biology files for listing on HKEX with a total of eight candidate drugs, three of which are in the late stage.

According to the disclosure on June 27 by the Hong Kong Stock Exchange, Jingze Biopharmaceutical (Hefei) Co., Ltd.-B (referred to as "Jingze Biopharmaceutical") has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and Guoyuan International as its joint sponsors. According to the prospectus, Jingze Biopharmaceutical is a biopharmaceutical company focusing on two high-growth tracks - assisted reproductive drugs and ophthalmic drugs. With the clinical demand in mind, the company has established a comprehensive research and development system as well as commercial-scale production capacity. With its system capabilities, the company has independently developed multiple product pipelines and has advanced several high technological barrier and commercially promising drugs to the late clinical and commercialization stages. According to Frost & Sullivan data, as of June 20, 2025, the company is one of the Chinese companies with the most large molecule drugs in clinical phase in the fields of assisted reproduction and ophthalmology. As of the same date, one of the company's core products in the field of assisted reproductive treatment, JZB30 (rhFSH lyophilized powder injection), has been officially approved for commercialization, while one of the main products, JZB33 (rhFSH aqueous injection), has submitted an NDA. At the same time, the core product in the ophthalmic field, JZB05 (anti-VEGF intravitreal injection), is conducting Phase III clinical trials in more than 40 centers in mainland China. The company is committed to providing patients with high-quality, cost-effective, and stable products, and aims to become a leader in the domestic fields of assisted reproduction and ophthalmic drugs. To address the unmet clinical needs in the fields of assisted reproduction and ophthalmology, the company has built a rich product pipeline since its establishment. As of June 20, 2025, there are a total of eight candidate drugs, with three products in the late stages, including one candidate drug that has been approved for NDA; one candidate drug has submitted an NDA, and one product is in the Phase III clinical research stage. In addition, the company has multiple other candidate drugs in different clinical stages. The product portfolio covers the most prominent indications in the fields of assisted reproduction and ophthalmology. JZB30 is the company's first commercial product in the field of assisted reproductive treatment. It is a recombinant human follicle-stimulating hormone (rhFSH) lyophilized powder injection product developed for ovarian stimulation in assisted reproduction cycles. JZB30 is a biosimilar drug developed in comparison to the globally highest market share imported powder injection form product Gonagen in 2024 and the first quarter of 2025. The company has completed Phase I and Phase III clinical studies comparing JZB30 with the reference drug (Gonagen) for controlled ovarian stimulation in assisted reproductive technology. NDA for JZB30 was approved by the National Medical Products Administration in April 2025. The company is also developing indications for JZB30 to treat hypogonadotropic hypogonadism. JZB05 is expected to become the company's first commercial product in the ophthalmic field. It is a self-developed anti-VEGF intravitreal injection intended to treat wAMD, DME, and other FND. JZB05 is a biosimilar drug developed in comparison to the globally highest-selling ophthalmic drug and anti-VEGF drug Aflibercept (Eylea). According to Frost & Sullivan data, Eylea achieved annual sales of $9.5 billion in 2024. As of June 20, 2025, JZB05 has completed Phase I clinical trials comparing it head-to-head with the reference drug (Eylea) and has entered further comparative Phase III clinical trials. The company expects to complete Phase III clinical trials in the second half of 2026 and submit an NDA for market approval in the same year. In terms of finances, in the fiscal years 2023 and 2024, Jingze Biopharmaceutical's research and development expenses were approximately RMB 122 million and RMB 133 million, respectively; while the total losses for the respective years were approximately RMB 246 million and RMB 243 million.